Medical device penetration testing is an authorized, controlled effort to test whether a realistic weakness in a device or connected system can be used to create a meaningful security, safety, or operational consequence. Its purpose is not to produce a dramatic list of findings. Its purpose is to give the product team evidence for the decisions that keep the device safe, supportable, and ready for review.
A good test can reveal issues that a checklist, code review, or automated scanner may not expose on its own. It can also show that a concerning theoretical issue is not exploitable in the released configuration. Both outcomes are useful, provided the work is planned around the actual device, the people who use it, and the conditions in which it is installed, serviced, and updated.
The test should never be treated as a one-time hurdle at the end of development. A connected device may rely on software, mobile applications, cloud services, hospital networks, wireless connections, service tools, manufacturing controls, and third-party components. Each change can alter the paths that need to be understood. Penetration testing is most valuable when it strengthens the broader medical device cybersecurity plan and helps the team make decisions while there is still time to act on them.
Start With the Questions the Test Must Answer
The word "penetration test" can make a team picture a generic attempt to break into a network. That is too narrow for a medical device. Begin instead with the questions the test needs to answer for this product. Which interfaces could allow an unauthorized party to view, change, interrupt, or misuse a function? Could a weakness affect therapy, an alarm, diagnostic information, patient data, device availability, or a clinician's ability to use the product safely? What would have to be true for that path to be realistic?
Those questions turn a broad security exercise into a device-specific assessment. A bedside device on a hospital network, a home-use product paired with a mobile application, and a serviceable capital system might all have different exposure paths even when their software uses similar components. The test plan should reflect intended users, use environment, connectivity, access controls, maintenance model, and expected behavior when a connection is lost.
Build the scope from the current architecture and release configuration, not only from a product description. Include the device, external interfaces, connected services, relevant accessories, update path, service path, and any system that can meaningfully change device behavior or data. The threat-modeling guide is a useful companion at this stage because it helps the team identify assets, trust boundaries, plausible attack paths, and the controls a test should examine.
Define Rules That Protect the Product and Its Users
Before testing begins, agree on the rules of engagement. The tester needs written authorization, designated contacts, permitted systems and environments, testing windows, limits on disruptive activity, and an escalation path for an urgent finding. A production-connected system, a clinical environment, or a device supporting essential functions may require a carefully isolated test setup and stricter stop conditions than a software-only prototype.
Clear rules also make the results more useful. Record the version and configuration being tested, the accounts or access assumptions available to the tester, any interfaces intentionally excluded, and the tools or techniques likely to create noise in logs or connected systems. Without those details, a finding can be difficult to reproduce or apply to the released product.
NIST's technical guide to security testing and assessment frames testing as a process for planning the work, analyzing findings, and developing mitigation strategies. For a medical device program, that discipline matters because the output must support product and quality decisions, not just an isolated security report.
Test Real Interfaces and Plausible Attack Paths
A useful penetration test follows the ways a device can actually be reached. Depending on the product, that may include wireless connections, network services, removable media, physical ports, mobile applications, cloud APIs, remote support, service tools, update packages, user accounts, manufacturing provisioning, or connections to other clinical systems. The work should test both technical controls and the assumptions that make those controls meaningful.
Consider a service interface. It is not enough to ask whether the port is password protected. The test should consider who can reach it, whether credentials are unique and managed, whether the device distinguishes authorized commands from malformed ones, whether service activity is visible, and what happens if a connection or update is interrupted. For a connected service, the questions may include authentication, authorization, session handling, encryption, input validation, data handling, and the device's response when the service is unavailable.
Automated scanning can help identify known weaknesses, but it does not establish the practical consequence for a medical device. A general software issue may not be reachable in the released configuration. Conversely, a modest configuration weakness can matter if it enables access to an essential function or prevents the device from operating as intended. The tester and product team need to evaluate the full path from exposure to consequence.
Use More Than One Testing Perspective
A single perspective can leave important paths unexamined. An external assessment asks what an attacker could discover without a trusted account or physical access. An authorized-user assessment asks what a person with legitimate service, clinical, or support access could do beyond the role they should hold. Where it is relevant, the team can also examine the assumptions around connected suppliers, software updates, and systems that exchange data with the device.
These perspectives should be chosen for the product, not assembled into a generic checklist. A stand-alone device with a physical service port presents a different set of questions from a connected system with remote administration and a mobile application. The valuable outcome is a set of plausible paths that reflects how the device is installed, maintained, and used in the real world.
Keep routine operations in view while testing. A control can look strong in isolation yet be bypassed when a user recovers from a network interruption, a service technician works under time pressure, or an update has to be completed in a constrained environment. Reviewing these conditions makes it easier to distinguish a theoretical observation from a weakness that needs a product decision.
Connect Findings to Device Risk Decisions
Findings need more than a generic severity label. A useful review asks whether the described condition is present in the released product, what an attacker would need to exploit it, which existing controls limit the path, and what the outcome could be for the device, users, patients, or organization operating the system. This is where cybersecurity assessment needs to connect directly to risk management and clinical use rather than remain a separate engineering task.
The result may be a design change, additional access control, a configuration adjustment, a monitoring improvement, a labeling or service-process change, or a documented rationale for why the residual risk is acceptable. The point is not to insist that every finding has the same response. It is to make the reasoning visible and proportionate to the product's actual use.
FDA's cybersecurity guidance and FAQs explain that applicable premarket submissions for cyber devices must address secure processes, postmarket vulnerability management, and a software bill of materials. Penetration testing can help substantiate parts of that evidence, but it does not replace the broader design, quality, and lifecycle records that make the device's cybersecurity position coherent.
Verify the Response, Not Only the Original Finding
Once a finding leads to a change, the next task is to show that the selected response works without creating an unacceptable side effect. Retest the relevant attack path where practical. Confirm that the control behaves as intended, then run the regression checks that matter for device performance, connectivity, alarms, data, service operations, and the normal clinical workflow. A quick technical fix that complicates an urgent user action or introduces an update failure can create a new problem.
Keep the evidence connected from beginning to end: the test plan, scope, product version, finding, device-specific assessment, decision rationale, corrective action, verification results, and release approval. That trail makes the work easier to review internally and easier to maintain when the device, software, or connected environment changes later.
Use Testing Throughout the Product Lifecycle
Testing cadence should match the device and the changes it undergoes. An early assessment can help guide architecture before major design choices harden. A later test can evaluate the integrated product and planned release configuration. Additional testing may be warranted when the device gains a new interface, a mobile or cloud feature, remote support, a new update mechanism, a major software component, or a meaningful change to the intended use or deployment environment.
Post-market testing also needs a clear relationship to vulnerability management. A newly reported issue may call for focused validation of an exposure path, while an update may require security regression testing before release. The medical device vulnerability management guide explains how teams can receive, assess, prioritize, and document those decisions over time.
How Qualira Helps Make Testing Useful
Penetration testing is most useful when it is connected to the product decisions around it. Qualira helps medical-device teams align testing scope and findings with intended use, system architecture, risk management, design controls, quality processes, submission planning, and post-market responsibilities. That approach helps the team turn a security result into evidence that supports the program instead of a report that sits apart from it.
Explore Qualira's regulatory strategy, quality system, and medical device regulatory consulting support, or talk with the team about a testing question that is affecting an important program decision.
Frequently asked questions
What is penetration testing for a medical device?
Penetration testing is an authorized, controlled attempt to identify and validate security weaknesses in a device and the systems around it. For medical devices, the value is not simply finding a technical issue. It is understanding whether a realistic attack path could affect safety, essential performance, data, clinical workflow, or the ability to support the product.
When should medical device penetration testing happen?
Testing should begin early enough to influence architecture and design decisions, then be repeated as important interfaces, software, connected services, or intended uses change. A final premarket test can be useful, but it should confirm a mature program rather than reveal basic decisions too late to address efficiently.
Is penetration testing the same as a vulnerability scan?
No. A vulnerability scan can identify known software or configuration issues. Penetration testing goes further by evaluating whether a weakness can be used in the device's actual configuration and what the resulting consequence could be. Both can be useful inputs, but neither replaces device-specific risk management.
What should a medical device penetration test report include?
A useful report explains the scope and assumptions, the systems and versions assessed, the attack paths evaluated, evidence supporting each finding, the realistic impact on the device, and recommended actions. The product team should then connect the report to risk records, design decisions, corrective actions, verification, and any required submission documentation.
